|
 |
|
|||||||
|
|||||||||
Copyright ©ERS Journals Ltd 2002
Serum surfactant proteins-A and -D as biomarkers in idiopathic pulmonary fibrosis
Depts of 1 Medicine, 2 Biostatistics, 3 Occupational Medicine, National Jewish Medical and Research Centre, 4 Dept of Medicine, University of California, San Francisco, USA, 5 Sapporo Medical University, Sapporo, Japan, 6 University of Iowa Medical College, Iowa, USA
CORRESPONDENCE: K.E. Greene, Division of Pulmonary Medicine, National Jewish Medical and Research Centre, 1400 Jackson Street, Denver, CO 80206, USA. Fax: 1 3033981806
Keywords: biomarker, chronic beryllium disease, idiopathic pulmonary fibrosis, sarcoidosis, surfactant proteins, systemic sclerosis
Received: September 14, 2000
Accepted September 16, 2001
This work was supported by NIH No. HL-03724, the Cystic Fibrosis Foundation, NIH No. ES-06538, CDC/NIOSH CCU-81221, NIH No. M01 RR-0051, NIH No. HL-07638, NIH No. HL-60316, NIH No. ES-09607, NIH No. AI-35018, VA Merit, and NIH No. HL-56556.
Idiopathic pulmonary fibrosis (IPF) has a high mortality rate, and current therapies are only marginally effective. A serum biomarker that predicts clinical outcome would be useful to stage disease, indicate prognosis and the need for aggressive therapy, and help stratify patients for clinical trials.
The goals of this study were to determine whether serum levels of surfactant protein-A (SP-A) or surfactant protein-D (SP-D) would distinguish between IPF and other types of interstitial lung disease and whether serum SP-A or SP-D levels predict outcome in patients with IPF.
The authors found that serum SP-A and SP-D levels were significantly elevated in patients with IPF and systemic sclerosis compared to sarcoidosis, beryllium disease and normal controls, and that SP-D correlated with radiographic abnormalities in patients with IPF. In addition, the authors found that both serum SP-A and SP-D levels were highly predictive of survival in patients with IPF.
This is the largest North American data set of surfactant protein measurements in idiopathic pulmonary fibrosis and the first report using multivariate analysis comparing serum surfactant proteins-A and -D to other commonly measured predictors of survival in idiopathic pulmonary fibrosis. Based on these results, the authors propose that serum surfactant proteins may prove to be useful biomarkers in patients with idiopathic pulmonary fibrosis.
This article has been cited by other articles:
|
|
 |
|
  B. W. Kinder, K. K. Brown, F. X. McCormack, J. H. Ix, A. Kervitsky, M. I. Schwarz, and T. E. King Jr Serum Surfactant Protein-A Is a Strong Predictor of Early Mortality in Idiopathic Pulmonary Fibrosis Chest, June 1, 2009; 135(6): 1557 - 1563. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Prasse, C. Probst, E. Bargagli, G. Zissel, G. B. Toews, K. R. Flaherty, M. Olschewski, P. Rottoli, and J. Muller-Quernheim Serum CC-Chemokine Ligand 18 Concentration Predicts Outcome in Idiopathic Pulmonary Fibrosis Am. J. Respir. Crit. Care Med., April 15, 2009; 179(8): 717 - 723. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Samten, J. C. Townsend, Z. Sever-Chroneos, V. Pasquinelli, P. F. Barnes, and Z. C. Chroneos An antibody against the surfactant protein A (SP-A)-binding domain of the SP-A receptor inhibits T cell-mediated immune responses to Mycobacterium tuberculosis J. Leukoc. Biol., July 1, 2008; 84(1): 115 - 123. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Gunther, B. Enke, P. Markart, P. Hammerl, H. Morr, J. Behr, G. Stahler, W. Seeger, F. Grimminger, I. Leconte, et al. Safety and tolerability of bosentan in idiopathic pulmonary fibrosis: an open label study Eur. Respir. J., April 1, 2007; 29(4): 713 - 719. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Fraser, S. S. Bohlson, N. Jasinskiene, N. Rawal, G. Palmarini, S. Ruiz, R. Rochford, and A. J. Tenner C1q and MBL, components of the innate immune system, influence monocyte cytokine expression J. Leukoc. Biol., July 1, 2006; 80(1): 107 - 116. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. L. Sorensen, J. v. B. Hjelmborg, K. O. Kyvik, M. Fenger, A. Hoj, C. Bendixen, T. I. A. Sorensen, and U. Holmskov Genetic and environmental influences of surfactant protein D serum levels Am J Physiol Lung Cell Mol Physiol, May 1, 2006; 290(5): L1010 - L1017. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. D. Nathan Lung Transplantation: Disease-Specific Considerations for Referral Chest, March 1, 2005; 127(3): 1006 - 1016. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. A. Al-Salmi, J. N. Walter, G. N. Colasurdo, M. M. Sockrider, E. O. Smith, H. Takahashi, and L. L. Fan Serum KL-6 and Surfactant Proteins A and D in Pediatric Interstitial Lung Disease Chest, January 1, 2005; 127(1): 403 - 407. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. G. De Pasquale, L. F. Arnolda, I. R. Doyle, P. E. Aylward, D. P. Chew, and A. D. Bersten Plasma Surfactant Protein-B: A Novel Biomarker in Chronic Heart Failure Circulation, August 31, 2004; 110(9): 1091 - 1096. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Tourkina, P. Gooz, J. C. Oates, A. Ludwicka-Bradley, R. M. Silver, and S. Hoffman Curcumin-Induced Apoptosis in Scleroderma Lung Fibroblasts: Role of Protein Kinase C{epsilon} Am. J. Respir. Cell Mol. Biol., July 1, 2004; 31(1): 28 - 35. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. S. Phelps, T. M. Umstead, M. Mejia, G. Carrillo, A. Pardo, and M. Selman Increased Surfactant Protein-A Levels in Patients With Newly Diagnosed Idiopathic Pulmonary Fibrosis Chest, February 1, 2004; 125(2): 617 - 625. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Lappi-Blanco, R. Kaarteenaho-Wiik, S. Salo, R. Sormunen, M. Maatta, H. Autio-Harmainen, Y. Soini, and P. Paakko Laminin-5 {gamma}2 Chain in Cryptogenic Organizing Pneumonia and Idiopathic Pulmonary Fibrosis Am. J. Respir. Crit. Care Med., January 1, 2004; 169(1): 27 - 33. [Abstract] [Full Text]
|
|
|
|
|
|
R. Janssen, H. Sato, J. C. Grutters, A. Bernard, H. van Velzen-Blad, R. M. du Bois, and J. M. M. van den Bosch Study of Clara Cell 16, KL-6, and Surfactant Protein-D in Serum as Disease Markers in Pulmonary Sarcoidosis Chest, December 1, 2003; 124(6): 2119 - 2125. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H Clark and K Reid The potential of recombinant surfactant protein D therapy to reduce inflammation in neonatal chronic lung disease, cystic fibrosis, and emphysema Arch. Dis. Child., November 1, 2003; 88(11): 981 - 984. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Zhang, W. Pao, S. M. Umphress, S. B. Jakowlew, A. M. Meyer, L. D. Dwyer-Nield, L. D. Nielsen, K. Takeda, E. W. Gelfand, J. H. Fisher, et al. Serum Levels of Surfactant Protein D Are Increased in Mice with Lung Tumors Cancer Res., September 15, 2003; 63(18): 5889 - 5894. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. H.Y. Green Overview of Pulmonary Fibrosis Chest, December 1, 2002; 122(6_suppl): 334S - 339S. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |